NCT04266509View on ClinicalTrials.gov

Study to Evaluate the Effect of Repeat-Dose Rifampin on the Pharmacokinetics (PK) of PF-06651600

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

June 25, 2020

Primary Completion Date

September 10, 2020

Study Completion Date

September 10, 2020

Conditions

Healthy Volunteers

Interventions

DRUG

PF-06651600

50 milligram (mg) tablet

DRUG

Rifampin

600 mg provided as two 300 mg capsules.

Trial Locations (1)

B-1070

Brussels Clinical Research Unit, Brussels

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY

NCT04266509 - Study to Evaluate the Effect of Repeat-Dose Rifampin on the Pharmacokinetics (PK) of PF-06651600 | Biotech Hunter | Biotech Hunter